Prevalence, risk factors and prognosis of nontuberculous mycobacterial infection among people with bronchiectasis: A population survey

Michal Shteinberg; Nili Stein; Yochai Adir; Shifra Ken-Dror; David Shitrit; Danielle Bendayan; Leonardo Fuks; Walid Saliba

doi:10.1183/13993003.02469-2017

Prevalence, risk factors and prognosis of nontuberculous mycobacterial infection among people with bronchiectasis: A population survey

Michal Shteinberg^*, Nili Stein, Yochai Adir, Shifra Ken-Dror, David Shitrit, Danielle Bendayan, Leonardo Fuks, Walid Saliba

^*Corresponding author for this work

Internal Medicine

Research output: Contribution to journal › Letter › peer-review

47 Scopus citations

Original language	English
Article number	1702469
Journal	European Respiratory Journal
Volume	51
Issue number	5
DOIs	https://doi.org/10.1183/13993003.02469-2017
State	Published - 1 May 2018

Funding

Funders	Funder number
AstraZeneca
GlaxoSmithKline
Novartis
Teva Pharmaceutical Industries

Access to Document

10.1183/13993003.02469-2017

Cite this

@article{189e46d073c6451f88d4c18fdb7f4888,

title = "Prevalence, risk factors and prognosis of nontuberculous mycobacterial infection among people with bronchiectasis: A population survey",

author = "Michal Shteinberg and Nili Stein and Yochai Adir and Shifra Ken-Dror and David Shitrit and Danielle Bendayan and Leonardo Fuks and Walid Saliba",

note = "Funding Information: Conflict of interest: M. Shteinberg reports having received research grants from Novartis and Trudell Pharma, travel grants from Actelion, BI, GSK and Rafa, and speaker{\textquoteright}s fees from BI, GSK, AstraZeneca, Teva and Novartis, and is a member of the EMBARC collaboration. Y. Adir reports having received travel grants from Actelion, BI, GSK and Rafa, and speaker{\textquoteright}s fees from BI, GSK, AstraZeneca, Teva and Novartis.",

year = "2018",

month = may,

day = "1",

doi = "10.1183/13993003.02469-2017",

language = "אנגלית",

volume = "51",

journal = "European Respiratory Journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

number = "5",

}

TY - JOUR

T1 - Prevalence, risk factors and prognosis of nontuberculous mycobacterial infection among people with bronchiectasis

T2 - A population survey

AU - Shteinberg, Michal

AU - Stein, Nili

AU - Adir, Yochai

AU - Ken-Dror, Shifra

AU - Shitrit, David

AU - Bendayan, Danielle

AU - Fuks, Leonardo

AU - Saliba, Walid

N1 - Funding Information: Conflict of interest: M. Shteinberg reports having received research grants from Novartis and Trudell Pharma, travel grants from Actelion, BI, GSK and Rafa, and speaker’s fees from BI, GSK, AstraZeneca, Teva and Novartis, and is a member of the EMBARC collaboration. Y. Adir reports having received travel grants from Actelion, BI, GSK and Rafa, and speaker’s fees from BI, GSK, AstraZeneca, Teva and Novartis.

PY - 2018/5/1

Y1 - 2018/5/1

UR - http://www.scopus.com/inward/record.url?scp=85047355904&partnerID=8YFLogxK

U2 - 10.1183/13993003.02469-2017

DO - 10.1183/13993003.02469-2017

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

C2 - 29545278

AN - SCOPUS:85047355904

SN - 0903-1936

VL - 51

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - 5

M1 - 1702469

ER -

Prevalence, risk factors and prognosis of nontuberculous mycobacterial infection among people with bronchiectasis: A population survey

Funding

Access to Document

Other files and links

Cite this